Status:
COMPLETED
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
Lead Sponsor:
Pfizer
Conditions:
Pneumonia, Pneumococcal
Pneumococcal Infections
Eligibility:
All Genders
65+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adul...
Eligibility Criteria
Inclusion
- Male or female adults aged 65 years or older on the day of vaccination and able to fulfill study requirements.
Exclusion
- Previous vaccination with any licensed or experimental pneumococcal vaccine
- Residence in a nursing home, long-term care facility, or similar facility
- Known hypersensitivity to vaccination
- Immune deficiency or suppression
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
84496 Patients enrolled
Trial Details
Trial ID
NCT00744263
Start Date
September 1 2008
End Date
October 1 2013
Last Update
October 6 2014
Active Locations (159)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Tilburg, North Brabant, Netherlands, 5022 JB
2
Pfizer Investigational Site
Abbekerk, Netherlands, 1657 AH
3
Pfizer Investigational Site
Alkmaar, Netherlands, 1815 JD
4
Pfizer Investigational Site
Alkmaar, Netherlands, 1825 PV